Search results
Showing 136 to 150 of 187 results for advanced breast cancer
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer Number TA214...
This guidance has been updated and replaced by NICE technology appraisal guidance 687.
This guidance has been updated and replaced by NICE technology appraisal guidance 836.
This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.
Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.
This guidance has been updated and replaced by NICE technology appraisal guidance 816.
Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)
Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults.
Eribulin for the treatment of locally advanced or metastatic breast cancer (TA250)
This guidance has been updated and replaced by NICE technology appraisal guidance 423 and NICE technology appraisal guidance 515.
Evidence-based recommendations on bevacizumab (Avastin), with gemcitabine and carboplatin, for treating platinum-sensitive advanced ovarian cancer in adults.
This appraisal has been updated and replaced by NICE guideline CG81.
improvement concerning the referral of patients with breast symptoms (including those suspicious of breast...
NICE has developed a medtech innovation briefing (MIB) on the ATEC breast biopsy system
Awaiting development [GID-TA11089] Expected publication date: TBC
Magseed for locating impalpable breast cancer lesions (MIB236)
NICE has developed a medtech innovation briefing (MIB) on Magseed for locating impalpable breast cancer lesions .
Brain tumours (primary) and brain metastases in over 16s (NG99)
This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.